inTheMedia

Nonviral Platforms Streamline Gene Therapy Delivery

Nonviral Platforms Streamline Gene Therapy Delivery 150 150 Eyevensys

In an article reviewing advancements in DNA plasmids, Eyevensys is featured with other innovative companies developing nonviral gene therapy.

ARVO 2023: Eyevensys announces positive preclinical data demonstrating efficacy of EYS809 over aflibercept for wet AMD

ARVO 2023: Eyevensys announces positive preclinical data demonstrating efficacy of EYS809 over aflibercept for wet AMD 150 150 Eyevensys

Eyevensys presents data showing the efficacy and durability of EYS809, a dual-gene plasmid in development for the treatment of wet age-related macular degeneration (AMD).

Pharmtech Focus: Eyevensys Raises $12M in a Series B Plus Funding Round

Pharmtech Focus: Eyevensys Raises $12M in a Series B Plus Funding Round 150 150 Eyevensys

The $12M raised in a Series B Plus funding round will support development of Eyevensys’s EYS809 program for the treatment of wet age-related macular degeneration (AMD), a chronic eye disorder that causes blurred vision or a blind spot in the eye.

WSJ Pro VC Daily: Biotech Acquisitions Could Be Poised for Second-Half Rebound

WSJ Pro VC Daily: Biotech Acquisitions Could Be Poised for Second-Half Rebound 150 150 Eyevensys

Paris- and Cambridge, Mass.-based biotech company developing therapies for ophthalmic diseases raised $12 million in Series B+ funding, led by Korea Investment Partners.

GeneTherapyLive: Non-Viral Gene Therapy Eases Treatment Burden in Wet AMD

GeneTherapyLive: Non-Viral Gene Therapy Eases Treatment Burden in Wet AMD 150 150 Eyevensys

A non-viral gene therapy sustained drug-delivery product that delivers anti-VEGF to the eye may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients with wet AMD.

Can Gene Therapy Cure Blindness?

Can Gene Therapy Cure Blindness? 150 150 Eyevensys

LABIOTECH.eu reports on Eyevensys and other innovative companies developing gene therapy treatments with the potential to cure different forms of genetic blindness.

Women Worldwide Podcast: How Are You Innovating in Your Role?

Women Worldwide Podcast: How Are You Innovating in Your Role? 150 150 Eyevensys

Eyevensys CEO, Patricia Zilliox, discusses innovation as a key component of growth in the medical and pharmaceutical industry, what her work has taught her about fundraising, and the impact of the pandemic on her work.

OIS: Francine Behar-Cohen Presents “Innovative Non-Viral Therapies for the Treatment of Ocular Diseases”

OIS: Francine Behar-Cohen Presents “Innovative Non-Viral Therapies for the Treatment of Ocular Diseases” 150 150 Eyevensys

Watch Eyevensys Founder and Chief Innovation Officer, Prof. Francine Behar-Cohen, present at the OIS Ocular Drug Delivery Meeting, providing details about our innovative non-viral gene therapies for the treatment of ocular diseases and our active pipeline and strategy.

OIS Drug Delivery Innovation Showcase – Eyevensys from Healthegy on Vimeo.

Le Figaro: Eyevensys, the Ray of Hope for Treating Ophthalmological Diseases

Le Figaro: Eyevensys, the Ray of Hope for Treating Ophthalmological Diseases 150 150 Eyevensys

Eyevensys founder, Francine Behar-Cohen, and Scientific Director, Thierry Bordet talk to Le Figaro about the company’s innovative treatments and technology in development for treating eye diseases. (article and video)

OIS: Eyevensys CEO, Patricia Zilliox, Featured on OIS Retina Podcast

OIS: Eyevensys CEO, Patricia Zilliox, Featured on OIS Retina Podcast 150 150 Eyevensys

Listen to Patricia Zilliox, CEO of Eyevensys, discuss her background, her industry experience and expertise, and her passion for developing treatments to improve patient outcomes.

  • 1
  • 2